Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
A submission for 4mg and 8mg tablets of the melatonin MT1 and MT2 receptor agonist had been made under the...
Create an account to read this article
Already a subscriber?
With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.
A week after Pfizer bid $4.9bn to acquire Metsera, the biotech reported mid-stage data showing 28-week efficacy comparable to tirzepatide and a “placebo-like” rate of diarrhea.
Acquired after an FDA advisory panel rejection in 2021, the oxytocin analog nasal spray was being positioned as a second drug to market for the rare disease Prader-Willi syndrome.
The Swiss company believes new rigor in its internal decision-making and focus on best-in-class efficacy will deliver strong growth to 2030 and beyond.
With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.
The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
